10-QPeriod: Q1 FY1999

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 1999

Filed May 14, 1999For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed its quarterly report on Form 10-Q for the period ending March 30, 1999. This filing indicates the company's financial status and operational updates during the first quarter of 1999. As a development-stage biopharmaceutical company, investors would focus on progress in its product pipeline, clinical trials, and any strategic partnerships or licensing agreements that could drive future revenue. While specific financial figures and operational details are not provided in the excerpt, the filing would typically outline the company's cash position, research and development expenses, and any significant events or milestones achieved. Investors should look for updates on key drug candidates and their progress through regulatory approval processes, as well as any indication of financial runway to support ongoing development efforts.

Key Highlights

  • 1Filing Date: May 13, 1999
  • 2Period End Date: March 30, 1999
  • 3Company: Regeneron Pharmaceuticals, Inc. (REGN)
  • 4Form Type: 10-Q Quarterly Report
  • 5Indicates financial and operational status for Q1 1999
  • 6Content expected to include R&D updates and pipeline progress

Frequently Asked Questions

This 10-Q filing provides a quarterly update on Regeneron Pharmaceuticals, Inc.'s financial performance and operational activities for the period ending March 30, 1999. It allows investors to monitor the company's progress and make informed decisions.

Investors should look for updates on the company's product pipeline, progress in clinical trials, research and development expenditures, cash burn rate, and any new strategic partnerships or licensing agreements. These factors are crucial for assessing Regeneron's future growth potential.

The provided excerpt is a directory listing of the SEC filing and does not contain specific financial details such as revenue, expenses, or profitability. Investors would need to access the full 10-Q document to find this financial data.